Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 14/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 13/20 | 0.46 |
| ▸ | PDE4A | P27815 | 12/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 12/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5022869 | 0.90 | PDE4B (0.56) | PDE4BPDE4DPDE4APDE4CMAPT | |
| SCHEMBL8298189 | 0.89 | PDE4B (0.62) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL8299625 | 0.87 | PDE4B (0.53) | PDE4BPDE4DPDE4APDE4CCYP19A1 | |
| SCHEMBL8298827 | 0.85 | PDE4B (0.64) | PDE4BPDE4DPDE4APDE4CMAPT | |
| SCHEMBL3995780 | 0.83 | KMT2A (0.46) | PDE4BPDE4DPDE4APDE4CCYP19A1 | |
| SCHEMBL8302112 | 0.83 | NPC1 (0.46) | CYP19A1CYP11B1CYP11B2MAPTTSHR | |
| SCHEMBL8301443 | 0.83 | PDE4B (0.47) | PDE4BPDE4DPDE4APDE4CCYP19A1 | |
| SCHEMBL14174070 | 0.82 | PDE4B (0.52) | PDE4BPDE4DPDE4APDE4CTSHR | |
| SCHEMBL5022827 | 0.80 | PDE4B (0.54) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL8353862 | 0.80 | PDE4B (0.54) | PDE4BPDE4DPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004111044-A1 | TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS:PROCESS FOR THEIR PREPARATION | GLENMARK PHARMACEUTICALS LTD. (US) | 2004-12-23 | — | — | WO | disclosed |